# Descriptive Observational Study ALK-2016-CPHG

> **NCT03718117** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 73 (actual)

## Conditions studied

- NSCLC
- Crizotinib
- ALK Gene Rearrangement or ROS1 Gene Rearrangement

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT03718117
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-03
- **Primary completion:** 2020-07-01
- **Final completion:** 2020-07-01
- **Target enrollment:** 73 (ACTUAL)
- **Last updated:** 2024-09-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03718117

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03718117, "Descriptive Observational Study ALK-2016-CPHG". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT03718117. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*